SK10282002A3 - Prostriedok na liečenie a/alebo prevenciu porúch metabolizmu lipidov a alergických foriem - Google Patents

Prostriedok na liečenie a/alebo prevenciu porúch metabolizmu lipidov a alergických foriem Download PDF

Info

Publication number: SK10282002A3
Authority: SK; Slovakia
Prior art keywords: carnitine; glucan; composition; isovaleryl; fumarate
Prior art date: 2000-11-17

Application number

SK1028-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Pietro Pola

Original Assignee

Sigma-Tau Healthscience S. P. A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-17

Filing date

2001-07-24

Publication date

2003-03-04

2001-07-24 Application filed by Sigma-Tau Healthscience S. P. A. filed Critical Sigma-Tau Healthscience S. P. A.

2003-03-04 Publication of SK10282002A3 publication Critical patent/SK10282002A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 31
230000000172 allergic effect Effects 0.000 title claims abstract description 5
208000010668 atopic eczema Diseases 0.000 title claims abstract description 5
230000002265 prevention Effects 0.000 title abstract description 4
208000017170 Lipid metabolism disease Diseases 0.000 title abstract description 3
IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims abstract description 18
229920001503 Glucan Polymers 0.000 claims abstract description 16
206010028980 Neoplasm Diseases 0.000 claims abstract description 5
150000004676 glycans Chemical class 0.000 claims abstract description 5
238000000034 method Methods 0.000 claims abstract description 5
229920001282 polysaccharide Polymers 0.000 claims abstract description 5
239000005017 polysaccharide Substances 0.000 claims abstract description 5
230000008569 process Effects 0.000 claims abstract description 4
239000003814 drug Substances 0.000 claims abstract description 3
235000015872 dietary supplement Nutrition 0.000 claims abstract 4
235000013402 health food Nutrition 0.000 claims abstract 2
229920002498 Beta-glucan Polymers 0.000 claims description 28
FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 26
239000002253 acid Substances 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 12
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 12
VUJGONMDLUDXIA-UTONKHPSSA-N C(C=CC(=O)O)(=O)O.C(CC(C)C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O Chemical compound C(C=CC(=O)O)(=O)O.C(CC(C)C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O VUJGONMDLUDXIA-UTONKHPSSA-N 0.000 claims description 10
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 7
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 7
239000013589 supplement Substances 0.000 claims description 6
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 5
QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 claims description 5
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims description 5
230000007123 defense Effects 0.000 claims description 5
239000000284 extract Substances 0.000 claims description 5
108010001062 polysaccharide-K Proteins 0.000 claims description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
229940009098 aspartate Drugs 0.000 claims description 4
230000001580 bacterial effect Effects 0.000 claims description 4
229960004203 carnitine Drugs 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
235000001497 healthy food Nutrition 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
208000035143 Bacterial infection Diseases 0.000 claims description 3
VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 3
208000036142 Viral infection Diseases 0.000 claims description 3
229940024606 amino acid Drugs 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 3
208000022362 bacterial infectious disease Diseases 0.000 claims description 3
239000005515 coenzyme Substances 0.000 claims description 3
230000009385 viral infection Effects 0.000 claims description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
HNSUOMBUJRUZHJ-REVJHSINSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-REVJHSINSA-N 0.000 claims description 2
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
235000006708 antioxidants Nutrition 0.000 claims description 2
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
235000013734 beta-carotene Nutrition 0.000 claims description 2
239000011648 beta-carotene Substances 0.000 claims description 2
229960002747 betacarotene Drugs 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
229960000304 folic acid Drugs 0.000 claims description 2
235000019152 folic acid Nutrition 0.000 claims description 2
239000011724 folic acid Substances 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
230000037356 lipid metabolism Effects 0.000 claims description 2
239000007937 lozenge Substances 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
239000006187 pill Substances 0.000 claims description 2
229940098084 pyridoxine 5 mg Drugs 0.000 claims description 2
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
235000020357 syrup Nutrition 0.000 claims description 2
239000006188 syrup Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
229940066528 trichloroacetate Drugs 0.000 claims description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
239000011782 vitamin Substances 0.000 claims description 2
229940088594 vitamin Drugs 0.000 claims description 2
229930003231 vitamin Natural products 0.000 claims description 2
235000013343 vitamin Nutrition 0.000 claims description 2
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
239000007787 solid Substances 0.000 claims 2
238000002560 therapeutic procedure Methods 0.000 claims 2
229940041514 candida albicans extract Drugs 0.000 claims 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
230000006735 deficit Effects 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000006196 drop Substances 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
-1 mucate Chemical compound 0.000 claims 1
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 claims 1
230000009467 reduction Effects 0.000 claims 1
235000000346 sugar Nutrition 0.000 claims 1
150000008163 sugars Chemical class 0.000 claims 1
239000012138 yeast extract Substances 0.000 claims 1
230000003213 activating effect Effects 0.000 abstract description 2
229940079593 drug Drugs 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 16
229960004857 mitomycin Drugs 0.000 description 9
241001465754 Metazoa Species 0.000 description 7
150000001875 compounds Chemical class 0.000 description 6
230000000694 effects Effects 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
229930192392 Mitomycin Natural products 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
230000000242 pagocytic effect Effects 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000007590 Calpain Human genes 0.000 description 1
108010032088 Calpain Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000015092 herbal tea Nutrition 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000164 trypan blue assay Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nutrition Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK1028-2002A 2000-11-17 2001-07-24 Prostriedok na liečenie a/alebo prevenciu porúch metabolizmu lipidov a alergických foriem SK10282002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2000RM000602A IT1317938B1 (it)	2000-11-17	2000-11-17	Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese
PCT/IT2001/000394 WO2002040012A1 (en)	2000-11-17	2001-07-24	Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms

Publications (1)

Publication Number	Publication Date
SK10282002A3 true SK10282002A3 (sk)	2003-03-04

Family

ID=11455002

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1028-2002A SK10282002A3 (sk)	2000-11-17	2001-07-24	Prostriedok na liečenie a/alebo prevenciu porúch metabolizmu lipidov a alergických foriem

Country Status (19)

Country	Link
US (1)	US7211571B2 (no)
EP (1)	EP1257267B1 (no)
AT (1)	ATE269073T1 (no)
AU (1)	AU778952B2 (no)
CA (1)	CA2406925A1 (no)
CZ (1)	CZ20022307A3 (no)
DE (1)	DE60103854T2 (no)
DK (1)	DK1257267T3 (no)
ES (1)	ES2222388T3 (no)
HU (1)	HUP0204209A3 (no)
IL (1)	IL150637A0 (no)
IT (1)	IT1317938B1 (no)
MX (1)	MXPA02007001A (no)
NO (1)	NO20023117D0 (no)
PL (1)	PL355200A1 (no)
PT (1)	PT1257267E (no)
SK (1)	SK10282002A3 (no)
TR (1)	TR200401572T4 (no)
WO (1)	WO2002040012A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8173618B2 (en) *	2003-07-25	2012-05-08	University Of Massachusetts	Formulations for reducing neuronal degeneration
US8597640B2 (en) *	2007-10-31	2013-12-03	University Of Massachusetts Lowell	Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
SG10201402287TA (en)	2009-05-11	2014-07-30	Berg Llc	Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
WO2012138765A1 (en)	2011-04-04	2012-10-11	Berg Pharma Llc	Methods of treating central nervous system tumors
MX380565B (es)	2013-04-08	2025-03-12	Berg Llc	Terapias combinadas de coenzima q10 para el tratamiento de cáncer.
AU2014315186B2 (en)	2013-09-04	2020-02-27	Berg Llc	Methods of treatment of cancer by continuous infusion of coenzyme Q10
US20170189350A1 (en)	2015-11-16	2017-07-06	Berg Llc	Methods of treatment of temozolomide-resistant glioma using coenzyme q10

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4975421A (en) *	1985-08-19	1990-12-04	Bioglucan, Lp.	Soluble phosphorylated glucan: methods and compositions for wound healing
US5977073A (en) *	1991-06-06	1999-11-02	Life Sciences' Technologies, Inc.	Nutrient composition for treatment of immune disorders
AUPN398295A0 (en) *	1995-07-05	1995-07-27	Carlton And United Breweries Limited	Chemical compounds and processes for their production
IT1277897B1 (it) *	1995-08-03	1997-11-12	Mendes Srl	Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre
IT1276253B1 (it) *	1995-12-15	1997-10-27	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1290801B1 (it) *	1996-07-05	1998-12-11	Mendes Srl	Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6080788A (en) *	1997-03-27	2000-06-27	Sole; Michael J.	Composition for improvement of cellular nutrition and mitochondrial energetics
ATE254923T1 (de)	1998-03-19	2003-12-15	Sigma Tau Ind Farmaceuti	Kombinierte zusammensetzung bestehend aus l- karnitin oder l-alkanoylkarnitin, einem glycosaminoglycan und/oder einem seiner bestandteile
KR20020075775A (ko)	1999-12-16	2002-10-05	시스킨드, 해리	영양제 조성물, 상기 조성물의 제조 방법 및 상기조성물의 사용 방법

2000
- 2000-11-17 IT IT2000RM000602A patent/IT1317938B1/it active
2001
- 2001-07-24 WO PCT/IT2001/000394 patent/WO2002040012A1/en not_active Ceased
- 2001-07-24 MX MXPA02007001A patent/MXPA02007001A/es active IP Right Grant
- 2001-07-24 PT PT01954335T patent/PT1257267E/pt unknown
- 2001-07-24 AT AT01954335T patent/ATE269073T1/de not_active IP Right Cessation
- 2001-07-24 DE DE60103854T patent/DE60103854T2/de not_active Expired - Fee Related
- 2001-07-24 TR TR2004/01572T patent/TR200401572T4/xx unknown
- 2001-07-24 ES ES01954335T patent/ES2222388T3/es not_active Expired - Lifetime
- 2001-07-24 HU HU0204209A patent/HUP0204209A3/hu unknown
- 2001-07-24 PL PL01355200A patent/PL355200A1/xx not_active Application Discontinuation
- 2001-07-24 IL IL15063701A patent/IL150637A0/xx unknown
- 2001-07-24 SK SK1028-2002A patent/SK10282002A3/sk unknown
- 2001-07-24 CA CA002406925A patent/CA2406925A1/en not_active Abandoned
- 2001-07-24 CZ CZ20022307A patent/CZ20022307A3/cs unknown
- 2001-07-24 AU AU76675/01A patent/AU778952B2/en not_active Ceased
- 2001-07-24 EP EP01954335A patent/EP1257267B1/en not_active Expired - Lifetime
- 2001-07-24 US US10/181,262 patent/US7211571B2/en not_active Expired - Fee Related
- 2001-07-24 DK DK01954335T patent/DK1257267T3/da active
2002
- 2002-06-27 NO NO20023117A patent/NO20023117D0/no unknown

Also Published As

Publication number	Publication date
IL150637A0 (en)	2003-02-12
PT1257267E (pt)	2004-09-30
HUP0204209A3 (en)	2005-03-29
PL355200A1 (en)	2004-04-05
DK1257267T3 (da)	2004-10-25
EP1257267B1 (en)	2004-06-16
US20030017999A1 (en)	2003-01-23
TR200401572T4 (tr)	2004-09-21
NO20023117L (no)	2002-06-27
ATE269073T1 (de)	2004-07-15
MXPA02007001A (es)	2003-01-28
ES2222388T3 (es)	2005-02-01
IT1317938B1 (it)	2003-07-15
DE60103854D1 (de)	2004-07-22
AU778952B2 (en)	2004-12-23
CA2406925A1 (en)	2002-05-23
ITRM20000602A1 (it)	2002-05-17
HUP0204209A2 (hu)	2003-04-28
ITRM20000602A0 (it)	2000-11-17
EP1257267A1 (en)	2002-11-20
DE60103854T2 (de)	2005-07-14
CZ20022307A3 (cs)	2003-01-15
NO20023117D0 (no)	2002-06-27
AU7667501A (en)	2002-05-27
WO2002040012A1 (en)	2002-05-23
US7211571B2 (en)	2007-05-01

Publication	Publication Date	Title
EP1117394B1 (en)	2003-09-17	Use of carnitines and resveratrol to produce a composition for the prevention or therapeutic treatment of cerebral disorders brought about by ageing and use of neurotoxic drugs
US20090148433A1 (en)	2009-06-11	Metallo-protein and tocotrienol (mp-t3) compositions and uses thereof
EP1257267B1 (en)	2004-06-16	Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms
US20130244973A1 (en)	2013-09-19	Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia
WO2010072209A2 (de)	2010-07-01	Nahrungsergänzungsmittel auf der basis von pantothensäure
US6552070B2 (en)	2003-04-22	Health food useful for preventing liver and biliary dysfunctions containing an alkanoyl L-carnitine and Silybum marianum extract
KR101729137B1 (ko)	2017-04-26	키토올리고당을 함유하는 피로회복용 조성물
US6780851B1 (en)	2004-08-24	Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan
PL201896B1 (pl)	2009-05-29	Zastosowanie propionylo-L-karnityny i kwercetyny
CZ20024A3 (cs)	2002-06-12	Přípravek k prevenci a léčbě dysfunkcí onemocnění ledvin
RU2751190C1 (ru)	2021-07-12	Антистрессовый напиток
WO2002040013A1 (en)	2002-05-23	Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin
US20150045424A1 (en)	2015-02-12	Composition useful for the treatment of type 2 diabetes
KR20160115883A (ko)	2016-10-06	키토올리고당을 함유하는 피로회복용 조성물
US20080293671A1 (en)	2008-11-27	Combination of Polychitosamine and Fibrate for the Prevention and Treatment of Hyperlipidemia
RU2001101919A (ru)	2003-01-20	Композиция, содержащая карнитин и инозит-фосфат, пригодная в качестве пищевой добавки или лекарства